FDA accepts app for Merck, Sanofi 6-in-1 combo vaccine

Gary Marshall--Courtesy of University of Louisville School of Medicine

Sanofi's ($SNY) Pentacel, which protects children against 5 serious diseases, nabbed the No. 3 spot on the world's list of best-selling vaccines last year. Whether an investigational 6-in-1 combo from the French drugmaker and partner Merck ($MRK) can eventually match its success remains to be seen, but the pair is now one step closer to finding out.

The FDA Monday accepted a Biologics License Application for the hexavalent prospect, DTaP5-IPV-Hib-HepB1, which protects against diphtheria, tetanus, pertussis (whooping cough), polio (poliovirus types 1, 2, and 3), and invasive disease caused by Haemophilus influenzae type b (Hib)--the same diseases Pentacel fends off--plus hepatitis B. The agency's decision deadline is undisclosed, and the application will undergo a standard 12-month review from its August filing date, a Merck spokeswoman told FierceVaccines.

University of Louisville School of Medicine professor Gary Marshall, who led the Phase III trial of the prospect, called results of that 1,400-infant trial encouraging, with the candidate showing similar immune responses against the antigens covered by Pentacel plus Merck's hep B vaccine Recombivax.

Sanofi Pasteur SVP of R&D John Shiver

Vaccines generally need to score key recommendations--as well as FDA approval--to see widespread uptake in the U.S. But as John Shiver, Sanofi Pasteur's SVP of R&D, pointed out in a statement, leading organizations--like the CDC's Advisory Committee on Immunization Practices (ACIP)--tend to smile on "the use of combination vaccines instead of individual injections."

If DTaP5-IPV-Hib-HepB1 can come anywhere close to Pentacel's sales, it'll be in good shape. Sanofi's blockbuster brought in $1.53 billion in worldwide sales last year, and EvaluatePharma predicts that haul will increase to $2.34 billion by 2020.

- read the release

Special Reports: Top 10 best-selling vaccines of 2013 | The top 5 vaccines by 2020 | The top 5 vaccine makers by 2013 revenue - Merck - Sanofi

Suggested Articles

The FDA is evaluating the possibility of prosecuting those involved in rogue herpes vaccine research led by a Southern Illinois University professor.

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

Experts say technology is advancing to develop vaccines faster at a time of increasing emerging disease outbreaks.